Qiagen : Q1 due 27 April at 22:05 CET – Expecting a strong start to the year
>Q1 helped by the pandemic and strong underlying demand - We forecast sales from products, which play an important role during the coronavirus pandemic, of $ 195m in Q1 2022, a decline of 3.9% y-o-y, solely due to adverse forex effects. Q1 2021 was strong and the $ 195m represent a meaningful q-o-q increase. However, this revenue line will eventually decline (we have $ 370m in FY 2022 sales in our model) with non-Covid related sales being more important. For Q1 we for...Qiagen is provider of Sample to Insight solutions to transform biological materials into valuable molecular insights. Co.'s sample technologies process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software interprets data. Automation solutions unite these together in molecular testing workflows. Co. provides these workflows to four classes: Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). Co. markets its products in more than 130 countries.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.